Review Article

Ferroptosis: Opportunities and Challenges in Myocardial Ischemia-Reperfusion Injury

Wei-kun Zhao,1 Yao Zhou,2,3 Tong-tong Xu,1 and Qi Wu

1Department of Health Care Ward, First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region 541001, China
2Department of Pathophysiology, Xuzhou Medical University, Xuzhou, Jiangsu province 221009, China
3Laboratory of Clinical and Experimental Pathology, Xuzhou Medical University, Xuzhou, Jiangsu province 221009, China
4Department of Physiology, Xuzhou Medical University, Xuzhou, Jiangsu province 221009, China

Correspondence should be addressed to Tong-tong Xu; xutongtongguilin@glmc.edu.cn and Qi Wu; wqak123@126.com

Received 18 March 2021; Revised 20 September 2021; Accepted 6 October 2021; Published 23 October 2021

Academic Editor: HAOBO LI

Copyright © 2021 Wei-kun Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ferroptosis is a newly discovered form of regulated cell death dependent on iron and reactive oxygen species (ROS). It directly or indirectly affects the activity of glutathione peroxidases (GPXs) under the induction of small molecules, causing membrane lipid peroxidation due to redox imbalances and excessive ROS accumulation, damaging the integrity of cell membranes. Ferroptosis is mainly characterized by mitochondrial shrinkage, increased density of bilayer membranes, and the accumulation of lipid peroxidation. Myocardial ischemia-reperfusion injury (MIRI) is an unavoidable risk event for acute myocardial infarction. Ferroptosis is closely associated with MIRI, and this relationship is discussed in detail here. This review systematically summarizes the process of ferroptosis and the latest research progress on the role of ferroptosis in MIRI to provide new ideas for the prevention and treatment of MIRI.

1. Introduction

Cell death is the natural endpoint of typical cells, occurring in growth and development, division and differentiation, and homeostatic metabolism, ultimately resulting in the irreversible end of the cellular function. The mode of cell death in the process of myocardial ischemia-reperfusion injury (MIRI) has been garnering substantial attention. Although cell death primarily constitutes apoptosis and necrosis, ferroptosis, a new form of programmed cell death that is iron-dependent and distinct from apoptosis and necrosis, has been discovered in recent years [1–3]. In recent years, ferroptosis has received extensive attention because it participates in the pathophysiological processes of tumor formation, kidney-related diseases, neurodegenerative diseases, stroke, and other diseases [4]. The occurrence and development of ferroptosis are closely related to the pathological process of myocardial cells, with ferroptosis participating in the pathogenic mechanisms of MIRI [5]. Ferritin was found to accumulate at the myocardial scar area of the left anterior descending coronary artery of mice in the ischemia-reperfusion injury (IRI) model after 30 min of ligation [6]. In addition, an in vitro study with perfused hearts showed that ferroptosis is crucial for the pathogenic mechanism of IRI; deferoxamine, a chelating agent, can prevent isolated hearts from IRI [7]. Erastin, an agonist of ferroptosis, can inhibit cystine ingestion and the downstream synthesis of glutathione, leading to an imbalance in cellular redox and, thus, cell death. In contrast, ferroptosis inhibitors can effectively alleviate organ injury induced by ischemic
reperfusion [8]. Ferroptosis is a type of cell death in the pathogenic process of MIRI, and its obstruction can lead to substantial protection of myocardial cells. In this paper, we focus on the recent research progress between ferroptosis and MIRI and discuss the important role of ferroptosis in the regulation of MIRI.

2. Ferroptosis

Early studies demonstrated that erastin and RAS-selective lethal compound 3 (RSL3) could cause cell death in a manner that is different from apoptosis, which can be inhibited by iron chelators and antioxidants [9–11]. In 2012, after continuous exploration and discussion of nonapoptosis cell death processes, Dixion and coworkers proposed an iron-dependent nonapoptosis cell death process, now known as ferroptosis [8]. This process involves the iron-dependent accumulation of reactive oxygen species (ROS) that exceeds the cell’s ability to maintain redox homeostasis, leading to lipid peroxidation and eventually causing cell death. Glutathione peroxidase-4 (GPX-4) is a key regulatory protein in ferroptosis [1]. The main morphological manifestations of ferroptosis are mitochondrial abnormalities, including reduced mitochondrial volume, mitochondrial cristae dissolution, and increased mitochondrial membrane density and rupture. However, whether mitochondrial damage can be reversed during the process of ferroptosis remains controversial [12]. The biochemical characteristics of ferroptosis mainly include the accumulation of iron and ROS, glutathione (GSH) depletion, the release of arachidonic acid, and inhibition of the cystine/glutamate antiporter system (System Xc- ) pathway [13]. Due to continuous research, a preliminary understanding of the process of ferroptosis began to take shape, and it has now been shown that ferroptosis is mainly regulated by multiple intracellular signaling pathways, such as iron homeostasis regulation, lipid peroxidation, System Xc-, and the voltage-dependent anion channel (VDAC) pathway [14–17] (Figure 1).

3. Ferroptosis Process

3.1. Regulatory Pathways of Iron Homeostasis. The maintenance and regulation of iron homeostasis are extremely complex processes. Iron is one of the most important essential trace elements in the human body and is involved in a series of important biological processes. Iron ions exist as Fe^{2+} and Fe^{3+} in the body and can be considered a “double-edged sword.” The element is also the primary raw material for the synthesis of hemoglobin and myoglobin and is crucial for important processes, such as electron transport, cellular respiration, DNA synthesis, cell proliferation and differentiation, and gene regulation. However, the excessive accumulation of iron ions can increase ROS production through the Fenton reaction, which affects iron stability and promotes iron deposition in vital organs, thereby leading to severe organ damage.

In the process of iron metabolism, divalent metal transporter-1 (DMT-1) is a key protein in the intracellular transport of iron. Fe^{3+} bound to transferrin enters the cell via the membrane protein, transferrin receptor-1 (TFR-1), to form endosomes. Free Fe^{2+} is reduced to Fe^{3+} in the endosomes by the metal reductase, six-transmembrane epithelial antigen of the prostate-3 (STEAP-3). Fe^{3+} is then transported from the endosomes to the labile iron pool in the cytoplasm under the mediation of DMT-1. This is the process of iron recycling [18]. Ferritin is involved in this process as a complex of iron storage proteins consisting of ferritin light chain (FTL) and ferritin heavy chain-1 (FTH-1) and participates in the regulation of iron ions as a multimer. FTH-1 has iron oxidase activity, which catalyzes the conversion of Fe^{2+} to Fe^{3+} and stores it in ferritin molecules, thereby reducing free iron levels, while FTL is directly involved in iron storage. In addition, heme oxygenase-1 (HO-1) was found to lead to ferroptosis by increasing intracellular iron and mediating lipid peroxidation reactions [19]. When intracellular iron homeostasis is disrupted, excess iron converts hydrogen peroxide and lipid peroxides to ROS via the Fenton reaction, which in turn causes ferroptosis [4, 20].

Various iron regulatory proteins are also involved in the process of iron metabolism. Iron-responsive element-binding protein-2 (IREB-2) also has an important function, which involves the enhanced expression of FTL and FTH-1, leading to decreased levels of intracellular iron and the inhibition of erastin-induced ferroptosis. This implies that the IREB-2 expression can indirectly interfere with iron adsorption and inhibit ferroptosis [1, 21]. In addition to IREB-2, recent studies have revealed that heat shock protein B-1 (HSPB-1) may also play a key role as an iron regulatory protein in iron metabolism. HSPB-1 can inhibit TFR-1, which results in lower iron ion concentration, thereby further suppressing the occurrence of ferroptosis [22]. Therefore, the regulation of iron homeostasis plays an important role in the process of ferroptosis.

3.2. Lipid ROS Production. The formation of lipid ROS is a key component in the onset and development of ferroptosis. ROS production depends on the action of polyunsaturated fatty acid-phosphatidyl ethanolamine (PUFA-PE). PUFA can be acylated under the catalysis of acyl-CoA synthetase long-chain family member-4 (ACSL-4) to produce PUFA acyl-CoA (PUFA-CoA), which then reacts with PE under the action of lysophosphatidylcholine acyltransferase-3 (LPAT-3) to produce PUFA-PE [16, 23, 24]. Under the enzymatic catalysis of lipoxigenase (LOX), PUFA-PE is essential for the formation of ROS [14, 17].

In this pathway, the action of PUFA-PE depends on two key regulatory points, ACSL-4 and LOX. Therefore, decreasing ACSL-4 and LOX can effectively inhibit the action of PUFA-PE and suppress the onset of ferroptosis [25]. The knockdown of the ACSL-4 gene in breast cancer cells can lead to a significant reduction in PUFA-PE production and suppress ferroptosis [26]. Furthermore, thiazolidinediones specifically inhibit ACSL-4, thereby suppressing ferroptosis [23, 27]. Zileuton (a 5-LOX inhibitor) can also inhibit erastin and ferroptosis in HT22 neuronal cells [28]. In addition, ROS formation is jointly achieved by a combination of iron-mediated Fenton reaction, the System Xc- pathway, and the VDAC pathway, which ultimately leads to ferroptosis.
3.3. System Xc- Pathway. System Xc- is an amino acid transporter expressed in the plasma membrane of mammalian cells. It is a heterodimer composed of SLC7A11 and SLC3A2, acting primarily through SLC7A11 (the primary active site of erastin). System Xc- exchanges extracellular cystine (Cys) for intracellular glutamate (Glu) at a 1:1 ratio, thus providing the raw material for intracellular GSH synthesis. Cellular uptake of cysteine is an important step in GSH production [29, 30]. GPX-4 is a GSH-dependent enzyme that converts GSH into oxidized glutathione (GSSG), which in turn can scavenge excess peroxides and hydroxyl radicals produced during cellular respiration and metabolism. Thus, GPX-4 plays an indispensable role in preventing lipid peroxidation [31]. When GPX-4 function is restricted, this is often accompanied by a decrease in GSSG and a significant increase in ROS [32]. Furthermore, the inhibition of GPX-4 activity will promote ROS formation and lipid peroxidation, thereby leading to ferroptosis. SLC7A11 gene silencing with siRNA interference substantially increased the sensitivity of HT-1080 cells to erastin-induced ferroptosis, while the overexpression of SLC7A11 in HT-1080 cells significantly enhanced cellular resistance to ferroptosis [33]. Another study found that the tumor suppressor P53 downregulated SLC7A11, inhibited System Xc-uptake of Cys, decreased GPX, increased ROS, and ultimately induced ferroptosis [34]. In addition, nicotinamide adenine dinucleotide phosphate (NADPH) was shown to maintain GSH in a reduced state, which further regulates ferroptosis [35]. Therefore, the inhibition of the System Xc- pathway will reduce intracellular GSH levels, resulting in decreased GPX-4 activity, which will ultimately lead to ferroptosis [30].

3.4. VDAC Pathway. VDAC is a channel protein for transporting ions and metabolites located on the outer mitochondrial membrane and consists of VDAC-1, VDAC-2, and VDAC-3. It controls the exchange of metabolites in the mitochondria and with other organelles [36]. In addition to regulating mitochondrial metabolism and energy production functions, VDAC can also potentially regulate cell survival and death signals by interacting with different ligands and proteins. Erastin, a typical inducer of ferroptosis, can...
activate VDAC in the presence of tubulin and cause mitochondrial hyperpolarization, thus leading to ROS production, mitochondrial dysfunction, and cell death [37]. When the VDAC-2 or VDAC-3 expression was inhibited by siRNA interference, cells were tolerant to erastin-induced ferroptosis. However, the overexpression of VDAC-2 or VDAC-3 did not increase cellular sensitivity to erastin. Therefore, VDAC may participate in cellular ferroptosis. In addition, mitochondria are key targets of the MIRI mechanism. The opening of the mitochondrial permeability transition pore (mPTP) can lead to elevated mitochondrial ROS production, membrane potential loss, and ATP depletion, thereby inducing cell death through mechanisms of programmed or non-programmed death. Meanwhile, erastin action on VDAC alters the permeability of the outer mitochondrial membrane, thus causing mitochondrial dysfunction, increased ROS production, and ultimately cellular ferroptosis [38–40]. Therefore, the VDAC pathway and mPTP may be involved in the mechanism of MIRI.

3.5. Other Related Signaling Pathways. At present, further in-depth investigations have led to the gradual recognition of the roles of NADPH oxidase-4 (NOX-4), HSPB-1, and other related proteins and signaling pathways in the regulation of ferroptosis [22, 41]. The mechanisms of ferroptosis are shown in Figure 1.

4. The Role of Ferroptosis in MIRI

4.1. Ferroptosis and MIRI. Myocardial ischemia caused by coronary artery obstruction is clinically manifested as persistent severe retrosternal pain and can lead to myocardial infarction, shock, arrhythmia, or heart failure. The most common treatment strategy is the early restoration of blood flow to the ischemic area using techniques, such as coronary angioplasty, percutaneous coronary intervention, and coronary artery bypass grafting (CABG), which can restore myocardial oxygen and nutrient supply, salvage the ischemic myocardium, and save the patient’s life.

MIRI is a phenomenon wherein cardiac function does not improve but worsens immediately after perfusion is restored to the ischemic myocardium. The pathogenic mechanism of MIRI is not fully understood. At present, it is known to primarily be involved in processes such as oxidative stress, calcium overload, and in inflammatory reactions [42]. Oxidative stress can lead to cell membrane rupture, swelling, or death through intracellular homeostasis, mitosis, cellular differentiation, and intracellular signaling [43]. As research progresses, ferroptosis has been identified as a form of cell death in MIRI pathogenesis that is closely related to oxidative stress. At present, peroxydized phosphatidylethanolamine (PEox) has been identified as a predictive biomarker of ferroptosis, and Sparvero’s group was the first to apply gas cluster ion beam secondary ion mass spectrometry (GCIB-SIMS) as a technique to increase PEox in cardiomyocytes, which provided direct evidence for the occurrence of ferroptosis in cardiomyocytes [44]. Iron chelating agents can bind to iron ions in the plasma or tissues and promote their elimination via urea or bile, thereby reducing the iron content in the body. Deferoxamine is a frequently used iron-chelating agent. Furthermore, in a study of patients with coronary artery disease (CAD), when performing CABG, the intravenous infusion of deferoxamine 8 h after anesthesia was effective in ameliorating oxygen radical production and protecting the myocardium from reperfusion injury, with more pronounced benefits in patients with reduced left ventricular ejection fraction (LVEF) [45]. A previous study also showed that using nuclear magnetic resonance spectroscopy in perfusion experiments on isolated rabbit hearts and adding a certain concentration of deferoxamine at the early stage of perfusion could effectively attenuate reperfusion-induced free radical generation, thus achieving cardioprotective effects [46]. Most current studies investigating the role of ferroptosis in MIRI have mainly focused on endoplasmic reticulum stress (ERS) and ROS production, GPX-4, and the autophagy-dependent ferroptotic pathway.

4.1.1. ERS. Ferroptosis occurs with the production of ERS, and ERS-induced unfolded protein response plays an important role in the ferroptotic process. When changes in the calcium level and redox status of the endoplasmic reticulum (ER) lumen induce a decline in chaperone protein function, cells can activate the unfolded protein response and cause ERS. ERS disrupts Ca2+ homeostasis in the ER, leading to mitochondrial calcium overload and elevated ROS production, while the accumulation of ROS will activate downstream caspase family proteins through cascade amplification, thereby initiating the process of cellular damage. In addition, the ERS process is induced by upstream signaling proteins, including inositol-requiring enzyme-1, activating transcription factor-6 (ATF-6), and PKR-like ER kinase (PERK) [47]. The ERS response elicited by ferroptosis inducers plays a tandem role between ferroptosis and other types of cell death [48], mainly in the form of ERS-mediated activation of the PERK-eukaryotic initiation factor 2α (eIF2α)-ATF 4-CHOP pathway. The dissociation of PERK from binding immunoglobulin protein BiP will trigger the phosphorylation and subsequent activation of PERK. Furthermore, eIF2α is activated, leading to ATF 4 mRNA translation and the induction of downstream CHOP molecules. The CHOP-mediated apoptosis in ERS plays an important role in the MIRI process in rats [49].

Ferroptosis induces ERS-triggered apoptosis. Studies have found that ferroptosis can induce ERS activation by inhibiting the System Xc–mediated exchange of extracellular cystine for intracellular glutamate [50, 51]. The activation of the PERK- eIF2α-ATF 4 pathway accompanying the ESR response regulates the target gene of the unfolded protein response, CHOP, while the binding of CHOP to the corresponding promoter inducesthe expressions of PUMA, endoplasmic reticulum redox protein-1α, and B-cell lymphoma-2 (Bcl-2) [52, 53]. Furthermore, ferroptosis agonists can induce the PUMA expression but not the Bcl-2 expression, suggesting that the ferroptosis-induced PUMA gene expression was unable to induce apoptosis [54]. In addition, tumor necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) binds to the corresponding death receptors to form a death-inducing signaling complex, which in turn induces apoptosis. With the help of the death-inducing signaling complex, caspase-8 is activated, which can lead to the further
activation of caspase-3, caspase-6, and caspase-7, eventually resulting in apoptosis. Ferroptosis agonists also modulate the cellular activity induced by TRAIL [54]. The interaction between ferroptosis and the apoptotic molecule TRAIL can be mediated by the ERS-induced expression of PUMA molecules. This suggests that ferroptosis-induced ERS can act as a bridge between ferroptosis and apoptosis. MIRI has also been found to be closely associated with ERS [55].

Apoposis results from ferroptosis-induced ERS and its correlation with MIRI. In a rat MIRI model, it was found that erastin probably increases ERS, which further increases ferroptosis. Inhibition of ferroptosis can reduce myocardial cell injury, and the inhibition of ERS can alleviate ferroptosis and reduce MIRI. These findings suggest that ferroptosis is involved in ERS-associated MIRI. Furthermore, based on a MIRI model established by ligation of the left anterior descending branch of the coronary artery in diabetic rats, the tail vein injection of the ferroptosis inhibitor, ferrostatin-1, could attenuate ERS-induced ferroptosis in cardiomyocytes, while the ERS inhibitor, salubrinal, could also attenuate ferroptosis in cardiomyocytes. This suggests that the activation of ERS may exacerbate the process of ferroptosis in cardiomyocytes, while the occurrence of ferroptosis can further exacerbate ERS in cardiomyocytes, which can form a vicious circle [56]. Therefore, ferroptosis-induced ERS and the activation of ERS play crucial roles in apoptosis and are important apoptotic mechanisms in MIRI.

4.1.2. GPX-4. GPX-4 participates in the regulation of ferroptosis. GPX-4 is an endogenous antioxidant for selenium-dependent enzymes that serves as a core regulator in the ferroptotic signaling pathway. Under physiological conditions, GPX-4 can confer cellular protection by scavenging lipid peroxides, thus preventing iron-mediated lipid peroxidation and elevated lipid ROS, whereas GPX inactivation induces ROS lipid peroxidation and ferroptosis [57]. System Xc- mediates cysteine uptake and glutamate release to promote GSH synthesis, while GSH acts as a synergistic molecule of GPX-4 to assist in scavenging lipid peroxides for cellular protection. Erastin inhibits System Xc- and indirectly inactivates GPX-4, thus leading to the accumulation of lipid peroxides to promote the onset of ferroptosis [58]. The indirect or direct inactivation of GPX-4 is the classic induction mechanism of ferroptosis. ML162 and RSL3 induce ferroptosis by depleting GPX-4 [59]. In addition, GSH participates as a coenzyme in the breakdown of hydrogen peroxide by GPX-4; therefore, by inhibiting the intracellular activity, GSH and GPX-4 increase intracellular ROS levels and ultimately mediate ferroptosis.

GPX-4 mediates ferroptosis to regulate MIRI. A previous study demonstrated that the levels of iron and malondialdehyde (MDA) in reperfused rat hearts gradually increased with increasing reperfusion time, accompanied by a decrease in GPX-4 levels [60]. Notably, there is evidence showing that the specific overexpression of GPX-4 in mitochondria attenuates cardiac dysfunction in MIRI [61]. Furthermore, GPX-4 is involved in the pathogenesis of MIRI. GPX-4 is an important antioxidant enzyme upstream of the mitochondria that regulate ferroptosis and oxidative stress by catalyzing the conversion of reduced glutathione (GSH) to oxidized glutathione (GSSG). Moreover, the knockdown of GPX-4 in a glutathione-independent manner leads to the destruction of mitochondrial morphology and increased mitochondrial ROS production [62]. In turn, the large production of ROS and ferroptosis are important mechanisms leading to MIRI [63, 64]. Another study found that liproxstatin-1 inhibited ferroptosis by increasing GPX-4 levels, which decreased ROS levels and thus alleviated MIRI [65]. Therefore, in MIRI, increasing GPX-4 expression can inhibit ferroptosis and attenuate the negative effects of MIRI.

4.1.3. ROS. Pathogenic mechanism of ROS participation in MIRI. Oxidative stress, attributed to the enhanced production of ROS during MIRI, is the main cause of MIRI. Excessive ROS accumulation causes membrane lipid peroxidation and disrupts the barrier function of the cell membrane. Excessive oxidation of lipids, DNA, and proteins causes increased cardiomyocyte damage and ultimately cell death. The antioxidant system regulates redox homeostasis by controlling intracellular ROS levels and the interactions between normal cellular metabolism and pathophysiology. Increased expression of antioxidant enzymes protects tissues from oxidative stress and produces cardioprotection after myocardial reperfusion [66]. During reperfusion, myocardial tissue is reoxygenated as blood flow is restored with a sudden increase in ROS production during the first few minutes, which is one of the underlying pathogenic mechanisms causing MIRI.

Increasing ROS levels lead to ferroptosis. Ferroptosis occurs due to increased intracellular iron concentration and the depletion of the antioxidant GSH, which leads to increased levels of ROS and in turn causes lipid peroxidation and eventually cell death. It was found that lipid peroxidation may occur in the lysosomal membrane due to ROS accumulation and iron overload, while the permeabilization of the lysosomal membrane can lead to oxygen radical production, cell membrane degeneration, and increased GSH depletion [67]. Moreover, lysosomes can regulate iron homeostasis and cause a dramatic increase in ROS expression. In addition, under the participation of iron ions, ROS are produced in a nonenzymatic pathway. For example, free iron ions present in the unstable iron pool form Fe^{3+} and hydroxyl radicals in the presence of Fe^{3+} and H_{2}O_{2} through the Fenton reaction. Alternatively, Fe catalyzes the production of -OH through the Haber-Weiss reaction. The inhibition of GPX-4 causes an increase in ROS, whereas the overexpression of GPX-4 reduces ROS and thus cellular ferroptosis [62, 68]. The increase in ROS leads to lipid peroxidation and ferroptosis, which can be inhibited by the iron chelator deferoxamine [69]. On the other hand, higher levels of iron transporters will increase iron-mediated ROS, which subsequently leads to ferroptosis. Liproxstatin-1 has been shown to significantly inhibit ferroptosis and attenuate MIRI by reducing the accumulation of ROS from lipid peroxidation, protecting the structural integrity of mitochondria, increasing the levels of the GPX-4 protein, and reducing ROS levels [70].

ROS play a role in MIRI-mediated ferroptosis. Ferroptosis is highly correlated with cardiomyocyte death. During
Overexpression of SIRT-1, the car-...excess iron leads to cardiomyocyte death, while the inhibition of ROS production attenuates cardio-myocyte death [6]. Based on in vivo and in vitro models of MIRI, ROS levels were significantly elevated in MIRI myo-cardial tissues, while sirtuin-1 (SIRT-1) and SLC7A11 expression were downregulated, and p53 was highly expressed. Following the overexpression of SIRT-1, the cardiomyocytes showed a significant improvement in the extent of ferroptosis, reduction in ROS levels, upregulation of the SLC7A11 protein expression, and downregulation of the p53 protein expression. This suggests that ROS plays an important role in MIRI ferroptosis, and that the regulation of ROS may be related to the SIRT-1/p53/SLC7A11 signaling pathway [71].

4.1.4. Cellular Autophagy. Autophagy is an important mech-anism of MIRI. Autophagy is a precisely regulated, dynamically developing process that cleans up damaged organelles and proteins via lysosomes, and is a monitoring mechanism that is relatively conserved. It recycles the basic nutrients produced and plays an important role in maintaining the normal structure and function of the heart. This involves not only cell survival but also cell death [72, 73]. In MIRI, the molecular mechanism of autophagy consists mainly of mammalian target of rapamycin (mTOR) and beclin 1, which play indispensable roles at different phases of MIRI. mTOR exerts its effects in the myocardial ischemic phase by mediating AMPK/mTOR and PI3K/Akt/mTOR signaling pathway [74] and further in the reperfusion phase via the upregulation of the beclin 1 pathway [72, 75, 76]. The possible mechanisms of beclin 1 activation in MIRI mainly include the following: (1) the association of beclin 1 with the Bcl-2 protein. (2) ROS can act as an inducer to mediate beclin 1 autophagy during reperfusion injury. (3) ROS can decrease the activity of autophagy-associated proteins through oxidation, thus causing LC 3 lipiddation and autophagy. Therefore, autophagy is involved in MIRI [77].

Ferroptosis is closely related to autophagy. To a certain degree, ferroptosis is dependent on autophagy and involves the embryonic lethal abnormal vision-like protein-1 (ELAVL-1) and forkhead box C-1 (FOXC-1) [78]. ELAVL-1 is a protein-coding gene that regulates the gene expression by stabilizing RNA (TNF-α or VEGF-A) and is implicated in the processes of apoptosis and oxidative stress [79]. ELAVL-1 inhibits the inflammatory response in AMI and plays a role in MIRI, where the significant increase in ELAV-1 is accompanied by the excessive production of ROS and inflammatory cytokines [63, 80]. FOXC-1 plays a significant role as a transcription factor in cell growth and survival, as well as in cardiac disease [81]. FOXC-1 transcription activates ELAVL-1, and the ELAVL-1-mediated enhancement of the autophagic ferroptosis pathway has a significant impact on MIRI. During MIRI, decreased GSH and GPX-4 levels can lead to elevated ELAVL-1, which further inhibits enzyme function and cellular antioxidant capacity. ELAVL-1 also inhibits ferroptosis and MIRI, restores GPX-4 expression level, restores cardiomyocyte viability, and attenuates cardiomyocyte injury. Low levels of ELAVL-1 can inhibit MIRI-induced autophagy, suppress fer-roptosis, and attenuate myocardial infarct size and MIRI. In addition, a decrease in the FOXC-1 expression was followed by a decrease in ELAVL-1 level, suggesting that FOXC regulates the ELAVL-1 expression during MIRI. Thus, autophagy-dependent ferroptosis counteracts the effects of reduced ELAVL-1 and contributes to the onset of MIRI and the overproduction of lipid signaling. Therefore, the relationship between FOXC-1 and ELAVL-1, as well as its association with ferroptosis, could serve as useful targets against MIRI.

Autophagy regulates ferroptosis to participate in the path-ogenic mechanism of MIRI. Previous studies showed that fer-roptosis is different from cellular autophagy and other modes of cell death, whether in terms of cell morphology, biochemical characteristics, or the regulatory factors involved. However, recent studies have revealed an interconnection between autophagy and ferroptosis in cardiomyocytes during the course of MIRI, wherein the activation of ferroptosis depends on the induction of autophagy, and the regulatory proteins of autophagy may also be involved in the regulation of ferroptosis. In another study, iron ion levels and ROS were significantly enhanced in the cardiomyocytes of MIRI rats, whereas GPX-4 and GSH protein expressions were significantly reduced, thus suggesting that ferroptosis may be involved in the pathogenesis of MIRI. Further studies revealed that myocardial ferroptosis may be regulated by autophagy-related signaling pathways during the progression of MIRI, and the ELAVL-1 protein is able to bind specifically with the autophagy-related protein beclin 1 to promote the decrease in the P62 protein expression and increase in LC 3 levels. This will induce an increase in the autophagy levels of cardiomyocytes and thus activate the ferroptotic pathway [80]. At present, in-depth studies have been conducted on the role of autophagy in ferroptosis in fields, such as cancer. However, in MIRI, most studies have only superficially concluded that ferroptosis in cardiomyocytes may be regulated by autophagy, while its underlying mechanisms of action remain poorly understood. Therefore, we hope that more in-depth studies will be conducted in this area in the future, so as to achieve new breakthroughs in the treatment of MIRI.

4.2. Treatment. There is currently no effective treatment for MIRI. With the advancement of research, researchers began identifying the inhibition of ferroptosis cardiomyocytes as a potentially important target for the treatment of MIRI [12]. Pretreatment of MIRI mice with ferrostatin-1 (Fer-1, an inhibitor of ferroptosis) or dexrazoxane (an iron chelating agent) significantly increased the expression level of Ptg2 mRNA, which further led to a reduction in the myocardial enzyme spectrum and the scar area of myocardial infarction [64]. In contrast, liproxstatin-1 (Lip-1) treatment maintained the structure and function of mitochondria after MIRI by reducing VDAC-1 levels and restoring GPX4 protein levels [70]. Overexpression of USP22 and inhibition of glutaminase can alleviate MIRI by inhibiting ferroptosis [7, 71]. In a MIRI rat model and oxygen–glucose deprivation/reoxygenation (OGD/R) H9c2 cells, it was found that ACSL 4-mediated ferroptosis was a promising target for MIRI treatment, and baicalin can prevent MIRI by inhibiting ACSL-4-mediated ferroptosis [82].
A recent study found that dexrazoxane or ponatinib inhibited ferroptosis during MIRI, and a combined treatment with both drugs markedly reduced the scar area of myocardial infarction. However, for myocardial infarction patients with an elevated ST section, percutaneous coronary intervention before myocardial reperfusion could not significantly reduce the scar area of myocardial infarction [83]. Based on these findings, a combined treatment targeting different types of cell death is proposed as an effective treatment strategy for MIRI.

### Table 1: Small molecules, drugs, and ferroptosis.

| Small molecules or drugs | Intervention target | Molecular weight | Molecular formula | Function | Experimental cells/animals | References |
|-------------------------|---------------------|------------------|-------------------|----------|-----------------------------|------------|
| Erastin                 | VDAC 2/3 or system Xc<sup>-</sup> | 547.04 | C30H31CIN4O4 | Prevents cystine import, causes GSH exhaustion, cause ferroptosis | BJeLR HT1080 143B p<sup>+</sup> and p<sup>−</sup> cell U2OS DU-145 | [1, 9, 10, 51, 88] |
| RSL3                    | GPX-4               | 440.9 | C23H21CIN2O5 | Covalent inhibitor of GPX-4 that causes accumulation of lipid hydroperoxides and ferroptosis | KBM7 MIA PaCa-2 A549, Calu-1, HCT116, HT1080 BJeLR | [10, 89] |
| Buthionine sulfoximine  | GSH exhaustion      | 222.305 | C8H18N2O3S | Cause ferroptosis | | [51] |
| Acetaminophen           | GSH exhaustion      | 151.163 | C8H9NO2 | Cause ferroptosis | HepG2/primary mouse | [90] |
| Sulphasalazine          | System Xc<sup>+</sup> | 398.394 | C18H14N4O5S | Low potency inhibitor that prevents cystine import, causes GSH depletion and ferroptosis | BJeLR/HT1080 HT1080/Cali-1 | [1, 51] |
| Sorafenib               | System Xc<sup>+</sup> | 464.825 | C21H16ClF3N4O3 | Cause ferroptosis | HT1080/Cali-1DU-145 nude mice | [51, 91–93] |
| Artesunate              | —                   | 384.421 | C19H28O8 | Cause ferroptosis | PDAC cell lines | [94] |
| Piperazine erastin      | VDACs or system Xc<sup>−</sup> | 645.19 | C35H41CIN6O4 | Cause ferroptosis | BJeLR nude mice | [88] |
| Trolox                  | Lipophilic antioxidants | 250.29 | C14H18O4 | Blocks propagation of lipid peroxidation, may inhibit lipoxygenases, inhibiting ferroptosis | H1080/PUF oxidant-induced death model on S. cerevisiae | [1, 95] |
| Ebselen                 | Oxidative pathway of ROS from lipid peroxidation | 274.17666 | C13H9NOSe | Inhibiting ferroptosis | HT1080, Calu-1 | [1] |
| SSRS 11-92              | —                   | —     | — | Inhibiting ferroptosis | HD model | [95] |
| α-Tocopherol (vitamin E)| Oxidative pathway of ROS from lipid peroxidation | 430.71 | C29H50O2 | Blocks propagation of lipid peroxidation, may inhibit lipoxygenases, inhibiting ferroptosis | BReLR GPX4-deficient T-cell mice | [10, 96] |
| Deferoxamine            | Fenton reaction     | 560.68 | C25H48N6O8 | Depletes iron and prevents iron-dependent lipid peroxidation, inhibiting ferroptosis | Wild-type and Bax/Bak | [1] |
| Deferoxamine mesylate (DFO) | Intracellular iron of ROS from lipid peroxidation | 656.8 | C25H48N6O8•CH4O3S | Inhibiting ferroptosis | BJeLR | [10] |
| SRS 16-86               | ROS from lipid peroxidation | 432.2525 | C16H24N2O2 | Inhibiting ferroptosis | HT1080/NIH 3T3 IRI mice model | [97] |
| Ferrostatin-1 (Fer-1)   | ROS from lipid peroxidation | 262.35 | C15H22N2O2 | Blocks lipid peroxidation, inhibiting ferroptosis | HT1080 | [1, 95] |
| Liproxstatin-1 (Lip-1)  | ROS from lipid peroxidation | 340.85 | C19H21CIN4 | Blocks lipid peroxidation, inhibiting ferroptosis | HRPTEpitCs GPX4<sup>−</sup> cells | [98] | GPX4<sup>−</sup> mice |
Recently, it was proven that phosphatidylcholine oxide content increased dramatically during MIRI, leading to reduced GPX-4 activity and ferroptosis. However, it is noteworthy that Fer-1 can inhibit OxPC-triggered ferroptosis [84]. Another study showed that the expression level of ELAVL-1 was upregulated. ELAVL-1 can also be activated by the autophagy-regulated ferroptosis process, which is related to FOXC-1 transcription, and ELAVL-1 knockout can reduce ferroptosis and alleviate MIRI [80]. Cyanidin-3-glucoside (C3G) treatment can effectively alleviate the expression of proteins related to apoptosis, reduce Fe²⁺ content, and improve MIRI. Therefore, C3G is a potential medicine to prevent myocardial cells from being affected by MIRI [85].

Ferroptosis has been shown to be related to diabetic MIRI. Fer-1 alleviates ERS, reduces cellular injury in H9c2 cells, and mitigates myocardial cell injury during diabetic MIRI. In addition, diabetes patients can induce MIRI by activating NOX-2-related oxidative stress and apoptosis, and inhibition of nicotinamide adenine dinucleotide phosphate oxidase-2 (NOX-2) can alleviate MIRI in diabetic rats [56, 86]. Fer-1 can also mitigate myocardial cell injury in H9c2 cells under hyperglycemic conditions and reduce H9c2 cell injury during anoxia/aerobiosis. These results have provided beneficial treatment for patients with diabetic MIRI.

Additionally, further understanding of the association between ferroptosis and MIRI after heart transplantation has been obtained. Fer-1 reduces myocardial cell death and blocks the recruitment of neutrophil granulocytes to damaged myocardial cells by damage-associated molecular patterns (DAMPs) after heart transplantation [87]. Therefore, targeted ferroptosis can potentially provide preventative treatment of MIRI in patients undergoing heart transplantation after coronary artery reperfusion. Other drugs, such as piperlongumine, thioredoxin, and artemisinin, may exert cardiomyocyte protective effects by inhibiting ferroptosis. However, articles related to the effects of Chinese medicines and other drugs on MIRI are still scarce, which warrants further investigation (see Table 1 for details).

5. Conclusion

Ferroptosis is an iron-dependent, nonapoptotic mode of cell death characterized by ROS accumulation. However, current research on ferroptosis is still in its infancy. Ferroptosis is closely associated with MIRI and regulates MIRI through ERS, ROS production, GPX-4, and the autophagy-dependent ferroptotic pathways. Ferroptosis can serve as an important target in MIRI, which may help in the process of reducing the occurrence of MIRI. Therefore, in-depth studies of ferroptotic mechanisms and possible interventions have now become a focus of current research. In addition, the precise stage of MIRI at which ferroptosis mainly occurs has not been located, and some studies have shown that the incidence of ferroptosis is different at different stages of MIRI [99]. Therefore, more in-depth investigations will provide new ideas for the prevention and treatment of MIRI.

**Abbreviations**

| Term          | Description                                         |
|---------------|-----------------------------------------------------|
| ACSL-4:       | Acyl-CoA synthetase long-chain family member-4      |
| AMI:          | Acute myocardial infarction                         |
| ATF-6:        | Activating transcription factor 6                   |
| Bcl-2:        | B-cell lymphoma-2                                   |
| CABG:         | Coronary artery bypass grafting                     |
| CAD:          | Coronary artery disease                             |
| Cys:          | Cysteine                                            |
| C3G:          | Cyanidin-3-glucoside                                |
| DAMPs:        | Damage-associated molecular patterns                |
| DMT-1:        | Divalent metal transporter 1                        |
| eIF2α:        | Eukaryotic initiation factor                         |
| ELAVL-1:      | Embryonic lethal-abnormal vision like protein 1      |
| ERS:          | Endoplasmic reticulum                               |
| ERS:          | Endoplasmic reticulum stress                         |
| Fer-1:        | Ferrostatin-1                                       |
| FOXC-1:       | Forkhead box C-1                                    |
| FTH-1:        | Ferritin heavy chain-1                              |
| FTL:          | Ferritin light chain                                 |
| GCIB-SIMS:    | Gas cluster ion beam secondary ion mass spectrometry|
| GPXs:         | Glutathione peroxidases                              |
| GPX-4:        | Glutathione peroxidase-4                            |
| GSH:          | Glutathione                                         |
| GSSG:         | Oxidized glutathione                                |
| GSSH:         | Glutathione hydopersulfides                         |
| HO-1:         | Heme oxygenase-1                                    |
| HSPB-1:       | Heat shock protein B-1                              |
| IREB-2:       | Iron responsive element-binding protein-2           |
| IRI:          | Ischemia-reperfusion injury                          |
| LOX:          | Lipoxygenases                                        |
| LPCAT-3:      | Lyso-phosphatidylcholine acyltransferase-3          |
| Lip-1:        | Lipoxygenin-1                                        |
| LVEF:         | Left ventricular ejection fraction                   |
| MDA:          | Malondialdehyde                                     |
| MIRI:         | Myocardial ischemia-reperfusion injury               |
| MPO:          | Myoperoxidase                                        |
| mTOR:         | Mammalian target of rapamycin                        |
| mPTP:         | Mitochondrial permeability transition pore           |
| NADPH:        | Nicotinamide adenine dinucleotide phosphate          |
| NOX-4:        | NADPH oxidase-4                                      |
| NOX-2:        | Nicotinamide adenine dinucleotide phosphate oxidase-2|
| OGD/R:        | Oxygen–glucose deprivation/reoxygenization          |
| PERK:         | PKR-like ER kinase                                  |
| PUFA-PE:      | Polyunsaturated fatty acid-phosphatidyl ethanolamine|
| PExo:         | Peroxidized phosphatidylethanolamine                 |
| ROS:          | Reactive oxygen species                              |
| RSL3:         | Ras selective lethal compound 3                     |
| SIRT-1:       | Sirtuin-1                                            |
| STEAP-3:      | Six transmembrane epithelial antigen of prostate-3   |
| System Xc:    | Cystine/glutamate antiporter system                  |
| TFR-1:        | Transferrin receptor-1                               |
| TLR-4:        | Toll-like receptor-4                                 |
TNF: Tumor necrosis factor
TRAIL: TNF-related apoptosis-inducing ligand
VDAC: Voltage-dependent anion channel.

Data Availability

The data used to support the finding of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Wei-kun Zhao and Qi Wu drafted and proofed the manuscript. Tong-tong Xu edited the manuscript. All authors shave agreed up on the submission and publication of this work. Wei-kun Zhao and Yao Zhou contributed equally to this work and should be considered co-first authors.

Acknowledgments

This study was sponsored by the National Natural Science Foundation of China (Grant No. 81760861 and No. 8210141573) and the Outstanding Talent Research Funding of Xuzhou Medical University (Grant No. D2019005 and No. D2019022).

References

[1] D. Tang, X. Chen, R. Kang, and G. Kroemer, “Ferroptosis: molecular mechanisms and health implications,” Cell Research, vol. 31, no. 2, pp. 107–125, 2021.
[2] H. T. Yu, P. Y. Guo, X. Z. Xie, Y. Wang, and G. Chen, “Ferroptosis, a new form of cell death, and its relationships with tumourous diseases,” Journal of Cellular & Molecular Medicine, vol. 21, no. 4, pp. 648–657, 2017.
[3] J. Zeng, Y. Chen, and X. Xu, “Research progress of ferroptosis-related mechanisms, regulation and diseases,” Chinese Pharmaceutical Journal, vol. 52, no. 4, pp. 253–257, 2017.
[4] J. P. F. Angeli, R. Shah, D. A. Pratt, and M. Conrad, “Ferroptosis inhibition: mechanisms and opportunities,” Trends in Pharmacological Sciences, vol. 38, no. 5, pp. 489–498, 2017.
[5] J. Lillo-Moya, C. Rojas-Solé, D. Muñoz-Salamanca, E. Panieri, L. Saso, and R. Rodrigo, “Targeting ferroptosis against ischemia/reperfusion cardiac injury,” Antioxidants (Basel), vol. 10, no. 5, p. 667, 2021.
[6] Y. Baba, J. K. Higa, B. K. Shimada et al., “Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 314, no. 3, pp. H659–H668, 2018.
[7] M. Gao, P. Monian, N. Quadri, R. Ramasamy, and X. Jiang, “Glutaminolysis and transferrin regulate ferroptosis,” Molecular Cell, vol. 59, no. 2, pp. 298–308, 2015.
[8] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht et al., “Ferroptosis: an iron-dependent form of nonapoptotic cell death,” Cell, vol. 149, no. 5, pp. 1060–1072, 2012.
[9] S. Dolma, S. L. Lessnick, W. C. Hahn, and B. R. Stockwell, “Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells,” Cancer Cell, vol. 3, no. 3, pp. 285–296, 2003.
[10] W. S. Yang and B. R. Stockwell, “Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells,” Chemistry & Biology, vol. 15, no. 3, pp. 234–245, 2008.
[11] N. Yagoda, M. von Rechenberg, E. Zaganjor et al., “RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels,” Nature, vol. 447, no. 7146, pp. 864–868, 2007.
[12] D. Wu and L. X. Chen, “Ferroptosis: a novel cell death form will be a promising therapy target for diseases,” Acta Biochimica et Biophysica Sinica, vol. 47, no. 10, pp. 857–859, 2015.
[13] C. J. Kang, X. T. Zhang, and W. A. Mei, “Progress in occurrence and development of ferroptosis,” Chinese Journal of Pathophysiology, vol. 33, no. 3, pp. 567–571, 2017.
[14] H. Z. Feng and B. R. Stockwell, “Unsolved mysteries: how does lipid peroxidation cause ferroptosis?,” PLOS Biology, vol. 16, no. 5, article e2006203, 2018.
[15] S. H. Hao, B. Liang, Q. Huang et al., “Metabolic networks in ferroptosis,” Oncology Letters, vol. 15, no. 4, pp. 5405–5411, 2018.
[16] B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir et al., “Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease,” Cell, vol. 171, no. 2, pp. 273–285, 2017.
[17] Z. Wen-Bo, K. Chen-Fei, Q. Gao-Wei, W. Yuan-Yuan, L. Xin, and W. Xiao-Feng, “Research progress on mechanism of ferroptosis,” Progress in Biochemistry and Biophysics, vol. 45, no. 1, pp. 16–22, 2018.
[18] D. J. Lane, A. M. Merlot, M. L. Huang et al., “Cellular iron uptake, trafficking and metabolism: key molecules and mechanisms and their roles in disease,” Biochimica et Biophysica Acta, vol. 1853, no. 5, pp. 1130–1144, 2015.
[19] M. Y. Kwon, E. Park, S. J. Lee, and S. W. Chung, “Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death,” Oncotarget, vol. 6, no. 27, pp. 24393–24403, 2015.
[20] H. Gao, Y. S. Bai, Y. Y. Jia et al., “Ferroptosis is a lysosomal cell death process,” Biochemical & Biophysical Research Communications, vol. 503, no. 3, pp. 1550–1556, 2018.
[21] E. Gammella, S. Recalcati, I. Rybinska, P. Buratti, and G. Cairo, “Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 230182, 10 pages, 2015.
[22] X. Sun, Z. Ou, M. Xie et al., “HSPB1 as a novel regulator of ferroptotic cancer cell death,” Oncogene, vol. 34, no. 45, pp. 5617–5625, 2015.
[23] S. Doll, B. Proneth, Y. Y. Tyurina et al., “ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition,” Nature Chemical Biology, vol. 13, no. 1, pp. 91–98, 2017.
[24] V. E. Kagan, G. Mao, F. Qu et al., “Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis,” Nature Chemical Biology, vol. 13, no. 1, pp. 81–90, 2017.
[25] J. H. Woo, Y. Shimon, W. S. Yang et al., “Elucidating Compound Mechanism of Action by Network Perturbation Analysis,” Cell, vol. 162, no. 2, pp. 441–451, 2015.
[26] H. Yuan, X. M. Li, X. Y. Zhang, R. Kang, and D. Tang, “Identification of ACSL4 as a biomarker and contributor of ferroptosis,” Biochemical & Biophysical Research Communications, vol. 478, no. 3, pp. 1338–1343, 2016.
[27] K. Shimada, R. Skoua, A. Kaplan et al., “Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis,” Nature Chemical Biology, vol. 12, no. 7, pp. 497–503, 2016.

[28] Y. Liu, W. Wang, Y. Y. Li, Y. Xiao, J. Cheng, and J. Jia, “The 5-lipoxygenase inhibitor zileuton confers neuroprotection against glutamate oxidative damage by inhibiting ferroptosis,” Biological & Pharmaceutical Bulletin, vol. 38, no. 8, pp. 1234–1239, 2015.

[29] L. Y. Wang, Y. C. Liu, T. du et al., “ATF3 promotes erastin-induced ferroptosis by suppressing system xc,” Cell Death and Differentiation, vol. 27, no. 2, pp. 662–675, 2020.

[30] M. Conrad and B. Proneth, “Broken hearts: iron overload, ferroptosis and cardiomyopathy,” Cell Research, vol. 29, no. 4, pp. 263–264, 2019.

[31] G. C. Forcina and S. J. Dixon, “GPX4 at the crossroads of lipid homeostasis and ferroptosis,” Proteomics, vol. 19, no. 18, article e1800311, 2019.

[32] R. Brigelius-Flohé and M. Maiorino, “Glutathione peroxidases,” Biochimica et Biophysica Acta, vol. 1830, no. 5, pp. 3289–3303, 2013.

[33] L. C. Chang, S. K. Chiang, S. E. Chen, Y. L. Yu, R. H. Chou, and W. C. Chang, “Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis,” Cancer Letters, vol. 416, pp. 124–137, 2018.

[34] L. Jiang, N. Kon, T. Y. Li et al., “Ferroptosis as a P53-mediated activity during tumour suppression,” Nature, vol. 520, no. 7545, pp. 57–62, 2015.

[35] K. Shimada, M. Hayano, N. Pagano, and B. R. Stockwell, “Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity,” Cell Chemical Biology, vol. 23, no. 2, pp. 225–235, 2016.

[36] M. Skonieczna, A. Cieslar-Pobuda, Y. Saenko et al., “The impact of DIDS-Induced inhibition of voltage-dependent anion channels (VDAC) on cellular response of lymphoblastoid cells to ionizing radiation,” Medicinal Chemistry, vol. 13, no. 5, pp. 477–483, 2017.

[37] J. J. Lemasters, “Evolution of voltage-dependent anion channel function: from molecular sieve to governor to actuator of ferroptosis,” Frontiers in Oncology, vol. 7, p. 303, 2017.

[38] D. M. Lin, B. Q. Cui, J. R. Ren, and J. Ma, “Regulation of VDAC1 contributes to the cardioprotective effects of penethylene glycol bilirubin hydrochloride during myocardial ischemia/reperfusion,” Experimental Cell Research, vol. 367, no. 2, pp. 257–263, 2018.

[39] Y. S. Feng, N. B. Madungwe, C. V. da Cruz Junho, and J. C. Bopassa, “Activation of G protein-coupled oestrogen receptor 1 at the onset of reperfusion protects the myocardium against ischemia/reperfusion injury by reducing mitochondrial dysfunction and mitophagy,” British Journal of Pharmacology, vol. 174, no. 23, pp. 4329–4344, 2017.

[40] N. B. Madungwe, N. F. Zilberstein, Y. Feng, and J. C. Bopassa, “Critical role of mitochondrial ROS is dependent on their site of production on the electron transport chain in ischemic heart,” American Journal of Cardiovascular Disease, vol. 6, no. 3, pp. 93–108, 2016.

[41] I. Poursaitidis, X. M. Wang, T. Crighton et al., “Onco-gene-Selective Sensitivity to Synchronous Cell Death following Modulation of the Amino Acid Nutrient Cystine,” Cell Reports, vol. 18, no. 11, pp. 2547–2556, 2017.

[42] H. K. Eltzhchig and T. Eckle, “Ischemia and reperfusion–from mechanism to translation,” Nature Medicine, vol. 17, no. 11, pp. 1391–1401, 2011.

[43] T. Kalogeri, C. P. Baines, M. Krenz, and R. J. Korthuis, “Cell biology of ischemia/reperfusion injury,” International Review of Cell and Molecular Biology, vol. 298, pp. 229–317, 2012.

[44] L. J. Šparvero, H. Tian, A. A. Amosco et al., “Direct mapping of phospholipid ferroptotic death signals in cells and tissues by gas cluster ion beam secondary ion mass spectrometry (GCIB-SIMS),” Angewandte Chemie(International ed. In English), vol. 60, no. 21, pp. 11784–11788, 2021.

[45] I. A. Paraskevaidis, E. K. Ilidromitidis, D. Vlahakos et al., “Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance,” European Heart Journal, vol. 26, no. 3, pp. 263–270, 2005.

[46] R. E. Williams, J. L. Zweier, and J. T. Flaherty, “Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts,” Circulation, vol. 83, no. 3, pp. 1006–1014, 1991.

[47] I. Tabas and D. Ron, “Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress,” Nature Cell Biology, vol. 13, no. 3, pp. 184–190, 2011.

[48] Y. S. Lee, D. H. Lee, H. A. Choudry, D. L. Bartlett, and Y. J. Lee, “Ferroptosis-induced endoplasmic reticulum stress: cross-talk between ferroptosis and apoptosis,” Molecular Cancer Research, vol. 16, no. 7, pp. 1073–1076, 2018.

[49] W. Zhang, Z. Sun, and F. Meng, “Schisandrin B ameliorates myocardial ischemia/reperfusion injury through attenuation of endoplasmic reticulum stress-induced apoptosis,” Inflammation, vol. 40, no. 6, pp. 1903–1911, 2017.

[50] R. J. Bridges, N. R. Natale, and S. A. Patel, “System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS,” British Journal of Pharmacology, vol. 165, no. 1, pp. 20–34, 2012.

[51] S. J. Dixon, D. N. Patel, M. Welsch et al., “Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis,” eLife Sciences, vol. 3, article e02523, 2014.

[52] A. P. Ghosh, B. J. Klocke, M. E. Ballestas, and K. A. Roth, “CHOP potentially co-operates with iFOXO3a in neuronal cells to regulate PUMA and BIM expression in response to ER stress,” PLoS ONE, vol. 7, no. 6, article e39586, 2012.

[53] H. Urra, E. Dufey, F. Lisbona, D. Rajas-Rivera, and C. Hetz, “When ER stress reaches a dead end,” Biochimica Biophysica Acta, vol. 1833, no. 12, pp. 3507–3517, 2013.

[54] S. H. Hong, D. H. Lee, Y. S. Lee et al., “Molecular crosstalk between ferroptosis and apoptosis: emerging role of ER stress-induced p53-independent PUMA expression,” Oncotarget, vol. 8, no. 70, pp. 115164–115178, 2017.

[55] X. Chen, Y. Wang, X. Xie et al., “Heme oxygenase-1 reduces sepsis-induced endoplasmic reticulum stress and acute lung injury,” Mediators of Inflammation, vol. 2018, no. 4, Article ID 9413876, 10 pages, 2018.

[56] W. Y. Li, W. Li, Y. Leng, Y. Xiong, and Z. Xia, “Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic reticulum stress,” DNA and Cell Biology, vol. 39, no. 2, pp. 210–225, 2020.
A. Alu, X. J. Han, X. L. Ma, M. Wu, Y. Wei, and X. Wei,
“Role of lysosome in regulated necrosis,” Nature, vol. 547, no. 7664, pp. 453–457, 2017.

C. Li, X. B. Deng, W. Zhang et al., “Novel allosteric activators for ferroptosis regulator glutathione peroxidase 4,” Journal of Medicinal Chemistry, vol. 62, no. 1, pp. 266–275, 2019.

D. Tang, R. Kang, T. V. Berge, P. Vandenaeele, and G. Kroemer, “The molecular machinery of regulated cell death,” Cell Research, vol. 29, no. 5, pp. 347–364, 2019.

L. J. Tang, X. J. Luo, H. Tu et al., “Ferroptosis occurs in phase of reperfusion but not necrosis in rat heart following ischemia or ischemia/reperfusion,” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 394, no. 2, pp. 401–410, 2021.

E. R. Dabbkowski, C. L. Williamson, and J. M. Hollander, “Mitochondria-specific transgenic overexpression of phospholipid hydroperoxide glutathione peroxidase (GPx4) attenuates ischemia/reperfusion-associated cardiac dysfunction,” Free Radical Biology & Medicine, vol. 45, no. 6, pp. 855–865, 2008.

A. Jelinek, L. Heyder, M. Daude et al., “Mitochondrial rescue prevents glutathione peroxidase-dependent ferroptosis,” Free Radical Biology & Medicine, vol. 117, pp. 45–57, 2018.

T. Y. Zhou, C. C. Chen, and Z. Li, “Molecular Characterization of Reactive Oxygen Species in Myocardial Ischemia- Reperfusion Injury,” Biomed research international, vol. 2015, Article ID 864946, 9 pages, 2015.

X. X. Fang, H. Wang, D. Han et al., “Ferroptosis as a target for protection against cardiomyopathy,” Proceedings of the National Academy of the United States of America, vol. 116, no. 7, pp. 2672–2680, 2019.

X. Wu, Y. Li, S. Zhang, and X. Zhou, “Ferroptosis as a novel therapeutic target for cardiovascular disease,” Theranostics, vol. 11, no. 7, pp. 3052–3059, 2021.

R. Rodrigo, J. C. Prieto, and R. Castillo, “Cardioprotection against ischaemia/reperfusion by vitamins C and E plus n-3 fatty acids: molecular mechanisms and potential clinical applications,” Clinical Science (London, England: 1979), vol. 124, no. 1, pp. 1–15, 2013.

A. Alu, X. J. Han, X. L. Ma, M. Wu, Y. Wei, and X. Wei, “The role of lysosome in regulated necrosis,” Acta Pharmacutica Sinica B, vol. 10, no. 10, pp. 1880–1903, 2020.

Y. Kinowaki, M. Kurata, S. Ishibashi et al., “Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma,” Laboratory Investigation, vol. 98, no. 5, pp. 609–619, 2018.

S. Doll and M. Conrad, “Iron and ferroptosis: a still ill-defined liaison,” International Union of Biochemistry and Molecular Biology Life, vol. 69, no. 6, pp. 423–434, 2017.

Y. S. Feng, N. B. Madungwe, A. D. Imam Aliagan, N. Tombo, and J. C. Bopassa, “Lipoxygenase-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels,” Biochemical and Biophysical Research Communications, vol. 520, no. 3, pp. 606–619, 2019.

S. Ma, L. Sun, W. Wu, J. Wu, Z. Sun, and J. Ren, “USP22 protects against myocardial Ischaemia–Reperfusion injury via the SIRT1-p53/SLC7A11–Dependent inhibition of ferroptosis-induced cardiomyocyte death,” Frontiers in Physiology, vol. 11, article 551318, 2020.

B. Shi, M. Ma, Y. Zheng, Y. Pan, and X. Lin, “MTOR and beclin1:two key autophagy-related molecules and their roles in myocardial ischemia/reperfusion injury,” Journal of Cellular Physiology, vol. 234, no. 8, pp. 12562–12568, 2019.

B. Zhou, J. Liu, R. Kang, D. J. Kliosnky, G. Kroemer, and D. Tang, “Ferroptosis is a type of autophagy-dependent cell death,” Seminars in Cancer Biology, vol. 66, pp. 89–100, 2020.

D. W. Zhang, Y. He, X. D. Ye et al., “Activation of autophagy inhibits nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome activation and attenuates myocardial ischemia-reperfusion injury in diabetic rats,” Journal of Diabetes Investigation, vol. 11, no. 5, pp. 1126–1136, 2020.

M. Aghaei, M. Molallebehzad, S. Ghorghanlu et al., “Targeting autophagy in cardiac ischemia/reperfusion injury: a novel therapeutic strategy,” Journal of cellular and comparative physiology, vol. 234, no. 10, pp. 16768–16778, 2019.

S. Wang, C. Wang, F. Yan et al., “N-Acetylcysteine attenuates diabetic myocardial ischemia reperfusion injury through inhibiting excessive autophagy,” Mediators of Inflammation, vol. 2017, Article ID 9257291, 10 pages, 2017.

D. Wu, K. F. Zhang, and P. F. Hu, “The role of autophagy in acute myocardial infarction,” Frontiers in Pharmacology, vol. 10, p. 551, 2019.

Y. L. Zhou, Y. Shen, C. Chen et al., “The crosstalk between autophagy and ferroptosis: what can we learn to target drug resistance in cancer?,” Cancer Biology & Medicine, vol. 16, no. 4, pp. 630–646, 2019.

S. Srikanth and M. Gorospe, “HuR function in disease,” Frontiers in Bioscience, vol. 17, no. 1, pp. 189–205, 2012.

H. Y. Chen, Z. Z. Xiao, X. Ling, R. N. Xu, P. Zhu, and S. Y. Zheng, “ELAVL1 is transcriptionally activated by FOXO1 and promotes ferroptosis in myocardial ischemia/reperfusion injury by regulating autophagy,” Molecular Medicine, vol. 27, no. 1, pp. 1–14, 2021.

S. Hannenhalli and K. H. Kaestner, “The evolution of fox genes and their role in development and disease,” Nature Reviews. Genetics, vol. 10, no. 4, pp. 233–240, 2009.

Z. Fan, L. Cai, S. Wang, J. Wang, and B. Chen, “Baicalin prevents myocardial ischemia/reperfusion injury through inhibiting ACSL4 mediated ferroptosis,” Frontiers in Pharmacology, vol. 12, article 628988, 2021.

W. Chan, A. J. Taylor, A. H. Ellims et al., “Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction,” Circulation. Cardiovascular Interventions, vol. 5, no. 2, pp. 270–278, 2012.

A. Stamenkovic, K. A. O’Hara, D. C. Nelson et al., “Oxidized phosphatidylcholines trigger ferroptosis in cardiomyocytes during ischemia-reperfusion injury,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 320, no. 3, pp. H1170–H1184, 2021.

X. Shan, Z. Y. Lv, M. J. Yin, J. Chen, J. Wang, and Q. N. Wu, “The Protective Effect of Cyanidin-3-Glucose on Myocardial Ischemia- Reperfusion Injury through Ferroptosis,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 880141, 15 pages, 2021.

C. Y. Wang, L. J. Zhu, W. L. Yuan et al., “Diabetes aggravates myocardial ischemia reperfusion injury via activating Nox2-related programmed cell death in an AMPK-dependent manner,” Journal of Cellular and Molecular Medicine, vol. 24, no. 12, pp. 6670–6679, 2020.
after heart transplantation,” *The Journal of Clinical Investigation*, vol. 129, no. 6, pp. 2293–2304, 2019.

[88] W. S. Yang, R. SriRamaratnam, M. E. Welsch et al., “Regulation of ferroptotic cancer cell death by GPX4,” *Cell*, vol. 156, no. 1-2, pp. 317–331, 2014.

[89] S. J. Dixon, G. E. Winter, L. S. Musavi et al., “Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death,” *ACS Chemical Biology*, vol. 10, no. 7, pp. 1604–1609, 2015.

[90] T. Lőrincz, K. Jemnitz, T. Kardon, J. Mandl, and A. Szarka, “Ferroptosis is involved in acetaminophen induced cell death,” *Pathology & Oncology Research*, vol. 21, no. 4, pp. 1115–1121, 2015.

[91] C. Louandre, I. Marcq, H. Bouhlal et al., “The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells,” *Cancer Letters*, vol. 356, no. 2, pp. 971–977, 2015.

[92] C. Louandre, Z. Ezzoukhry, C. Godin et al., “Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib,” *International Journal of Cancer*, vol. 133, no. 7, pp. 1732–1742, 2013.

[93] E. Lachaier, C. Louandre, C. Godin et al., “Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors,” *Anticancer Research*, vol. 34, no. 11, pp. 6417–6422, 2014.

[94] N. Eling, L. Reuter, J. Hazin, A. Hamacher-Brady, and N. R. Brady, “Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells,” *Oncoscience*, vol. 2, no. 5, pp. 517–532, 2015.

[95] R. Skouta, S. J. Dixon, J. Wang et al., “Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models,” *Journal of the American Chemical Society*, vol. 136, no. 12, pp. 4551–4556, 2014.

[96] M. Matsushita, S. Freigang, C. Schneider, M. Conrad, G. W. Bornkamm, and M. Kopf, “T cell lipid peroxidation induces ferroptosis and prevents immunity to infection,” *Journal of Experimental Medicine*, vol. 212, no. 4, pp. 555–568, 2015.

[97] A. Linkermann, R. Skouta, N. Himmerkus et al., “Synchronized renal tubular cell death involves ferroptosis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 47, pp. 16836–16841, 2014.

[98] J. P. Friedmann Angeli, M. Schneider, B. Proneth et al., “Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice,” *Nature Cell Biology*, vol. 16, no. 12, pp. 1180–1191, 2014.

[99] J. Peng and D. O. Pharmacology, “Ferroptosis: a new way of myocardial cell death after ischemia /reperfusion,” *Chinese Journal of Arteriosclerosis*, vol. 26, no. 8, pp. 757–760, 2018.